Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Biomaterials. 2017 Nov 20;156:194–203. doi: 10.1016/j.biomaterials.2017.11.022

Figure 2. ELISpot analysis of splenocytes from immunization with NY-ESO-1 formulations.

Figure 2

A) Vaccine components per dose of different formulation groups (a–f). B) Representative ELISpot data from splenocytes of immunized group, pulsed with irrelevant peptide (SIINFEKL) or relevant epitope peptide (NYESO). C) Summary of averaged ELISpot data, which evaluated antigen-specific IFN-γ secretion. HLA-A2 mice were immunized with different formulations (a–f), and splenocytes were pulsed ex vivo in the presence of relevant peptide (NYESO) or irrelevant peptide (SIINFEKL) and analyzed for specific IFN-γ secretion. Higher NY-ESO-1 epitope-specific IFN-γ secretion was observed for the group that received CpG-NYESO-E2. Data is presented as average ± S.E.M. of at least 3 independent experiments (n ≥ 3). Statistical significance was determined by two-way ANOVA followed by a Tukey's test (***p < 0.001; ****p < 0.0001).